SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ADAPTHEALTH CORP. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)

10/04/2021 | 04:44pm EDT

Item 5.02. Departure of Directors or Certain Officers? Election of Directors? Appointment of Certain Officers? Compensatory Arrangements of Certain Officers.

Appointment of Greg Belinfanti as Director

On September 30, 2021, following the recommendation of the nominating and governance committee of AdaptHealth Corp. (the "Company"), the Board of Directors of the Company (the "Board") appointed Greg Belinfanti to the Board. Mr. Belinfanti will serve as a Class I director until his term expires at the 2023 annual meeting of stockholders, at which time he will stand for election by the Company's stockholders. Mr. Belinfanti will serve on the executive committee, the compensation committee and the nominating and governance committee of the Board.

Mr. Belinfanti is a Senior Managing Director of One Equity Partners. Pursuant to that certain Investment Agreement, dated as of May 25, 2020, (the "Investment Agreement") by and among the Company, OEP AHCO Investment Holdings, LLC, a Delaware limited liability company ("OEP"), and, solely for purposes of Section 3.10 thereof, One Equity Partners VII, L.P., a Delaware limited partnership, OEP has the right, subject to its continuing ownership of a minimum number of shares of the Company's common stock, to nominate for election to the Board one individual designated by the Purchaser and one independent director nominated by the Company or the Board. The Company and OEP have agreed that, upon his appointment to the Board, Mr. Belinfanti will be OEP's designee to the Board contemplated by the Investment Agreement in place of Brad Coppens, who will remain as a member of the Board.

Mr. Belinfanti will receive the same compensation opportunities as the Company's other non-employee directors. The Board has determined that Mr. Belinfanti is "independent" within the meaning of the applicable rules and regulations of the Securities and Exchange Commission and the listing standards of the Nasdaq Stock Market. For more information on the Investment Agreement, please refer to the description thereof under the heading "Investment Agreement" in Item 1.01 of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 29, 2020 and the full text of the Investment Agreement, which is attached as Exhibit 10.1 to such Current Report on Form 8-K.

There were no other arrangements or understandings between Mr. Belinfanti and any other person pursuant to which Mr. Belinfanti was selected as a director. Mr. Belinfanti has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

On September 30, 2021, the Company entered into an indemnification agreement with Mr. Belinfanti in the form attached as Exhibit 10.4 to the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on November 14, 2019, which provides that, subject to limited exceptions, and among other things, the Company will indemnify Mr. Belinfanti to the fullest extent permitted by law for claims arising in his capacity as a director of the Company.

Item 9.01. Financial Statements and Exhibits.

(d)     Exhibits

   99.1     Press Release dated September 30, 2021.
 104      The cover page from this Current Report on Form 8-K, formatted in Inline

                                     - 2 -

© Edgar Online, source Glimpses

05/12ADAPTHEALTH CORP. : Entry into a Material Definitive Agreement, Financial Statements and E..
05/11Deutsche Bank Adjusts AdaptHealth Price Target to $22 From $28, Maintains Buy Rating
05/10ADAPTHEALTH CORP. Management's Discussion and Analysis of Financial Condition and Resu..
05/10AdaptHealth's Q1 Swings to Profit as Revenue Rises; Raises FY2022 Guidance
05/10Earnings Flash (AHCO) ADAPTHEALTH Posts Q1 Revenue $706.2M, vs. Street Est of $646.4M
05/03UBS Adjusts AdaptHealth Price Target to $18 From $20, Maintains Buy Rating
03/08RBC Cuts Price Target on AdaptHealth to $26 From $31, Citing Prolonged Philips Headwind..
03/07SECTOR UPDATE : Health Care Stocks See Small Uptick Off Midday Lows
03/07SECTOR UPDATE : Health Care Stocks Sinking in Monday Selloff
03/02SVB Leerink Lowers AdaptHealth's Price Target to $24 From $32, Maintains Outperform Rat..
More news
More recommendations
Duration : Period :
DFB Healthcare Acquisitions Corp. Technical Analysis Chart | AHCO | US23291E1091 | MarketScreener